10-K · April 30, 2026
Artiva Biotherapeutics, Inc. reported no revenue for the fiscal year ending December 31, 2025, continuing its clinical-stage focus on NK cell therapy, specifically AlloNK for refractory rheumatoid arthritis. The company…
Earnings analysis · 10-Q
ARTV earnings analysis
Filed May 8, 2026 · Our reading of the company's report
The latest report
Artiva Biotherapeutics reported a Q1 2026 net loss of $23.5 million, up from a loss of $20.3 million in Q1 2025, with EPS of -$0.95. The company remains without revenue, focusing on clinical development with positive…
Read full summary
Artiva Biotherapeutics reported a Q1 2026 net loss of $23.5 million, up from a loss of $20.3 million in Q1 2025, with EPS of -$0.95. The company remains without revenue, focusing on clinical development with positive updates on AlloNK trials, supported by cash reserves expected to last until Q2 2027.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.95
What stood out
-
Increased Net Loss YoY
Net loss for Q1 2026 was $23.5 million, compared to $20.3 million in Q1 2025.
-
No Revenue Yet Again
Artiva reported no revenue again for Q1 2026, same as prior periods.
-
Positive Clinical Data Announced
Positive preliminary results for AlloNK were highlighted with a 71% ACR50 response.
-
Extended Cash Runway
Cash reserves of $86.8 million are expected to last until Q2 2027.
-
Increased R&D Expense
R&D expenses rose to $19.3 million in Q1 2026 from $17.1 million in Q1 2025.
-
Regulatory Designations Received
Received Fast Track designation for AlloNK for refractory RA in January 2023.
What to watch
-
Continued Losses
The company posted an operating loss of $24.4 million, increasing financial strain.
-
No Revenue Generation
Artiva has not generated any revenue since inception, raising sustainability concerns.
-
Patent and Licensing Risks
Dependence on licenses with GC Cell risks loss of rights if obligations are not met.
Management's outlook
Management deferred revenue guidance as focus remains on clinical stage development.
Earlier filings 4
10-K · March 10, 2026
Artiva remains a clinical-stage NK cell therapy company prioritizing AlloNK for refractory rheumatoid arthritis, citing Fast Track designations and planned FDA interactions in H1 2026. Financially the company reported…
10-Q · November 12, 2025
Artiva reported no revenue for the quarter and a larger GAAP net loss versus prior-year quarter: a net loss of $21,528 (three months ended September 30, 2025) versus $17,472 in Q3 2024, while EPS modestly improved to…
10-K · March 24, 2025
Artiva (ARTV) is an early-stage, clinical-stage cell therapy company focused on an allogeneic, off‑the‑shelf NK cell product (AlloNK) for autoimmune diseases and cancers. The 10‑K emphasizes manufacturing-first strategy…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.